Leiden University Medical Center
Leiden, Netherlands
Martin Taphoorn, obtained his MD at the University of Leiden in 1984 and subsequently specialized in clinical neurology at the Free University in Amsterdam, where he also wrote his PhD thesis “Treatment of primary and metastatic brain tumours; beneficial and adverse effects” For his specialisation in neuro-oncology he During a sabbatical leave of 3 months he visited MD Anderson Cancer Center Houston Texas (Dr. Levin) and Memorial Sloan-Kettering Cancer Center New York (Dr. DeAngelis).
Subsequently he was clinical neurologist/neuro-oncologist at University Medical Center Utrecht, Haaglanden Medical Center The Hague and Leiden University Medical Center. He was appointed Professor of Neuro-Oncology in Amsterdam from 2007 until 2015, and since 2015 moved to Leiden University where he performed both preclinical and clinical research in Neuro-Oncology with an emphasis on neurotoxicity, cognitive functioning and quality of life.
From 2009-2011 he was president of the Netherlands Society of Neurology.
He is actively involved in both the EORTC Brain Tumor Group and EORTC Quality of Life Group, in both Groups he has been member of the executive committee Apart form being board member of EANO he was also member of the European CanCer Organisation (ECCO) board from 2014 to 2016.
At present he is chair of the Grant Review Committee of the EORTC Quality of Life Group and member of the Scientific Advisory Board of KWF Dutch Cancer Society.
From 2021 he is Editor in Chief of Neuro-Oncology Practice.
He has authored over 280 peer-reviewed articles, mainly on clinical outcome research in neuro-oncology.
Martin J.B. Taphoorn MD, PhD, neurologist and professor in neuro-oncology, Leiden University Medical Center and Medical Center Haaglanden, The Hague, The Netherlands.